BS

BioNTech SE

Q2 FY26Biotechnology

BioNTech SE Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹93

Market cap₹23.5K Cr

P/E-17.6

Updated29 May 2026

Read4 min read

What the Q2 FY26 call signalled

0 of 1 strong

RevenueSlow growth

The short version

- BioNTech reaffirms 2026 revenue guidance of $2 billion to $2.3 billion, despite lower COVID-19 vaccine demand. - BioNTech expects full-year 2026 total revenues in the range of $2 billion to $2.3 billion, despite lower COVID-19 vaccine sales.

From BioNTech SE's Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Slow growth

BioNTech reaffirms 2026 revenue guidance of $2 billion to $2.3 billion, despite lower COVID-19 vaccine demand.
COVID-19 vaccine revenues expected to decline in the US and Europe due to competitive and contracting markets.
Majority of 2026 revenue expected in last 4 months, following seasonal patterns.
Revenue growth supported by BMS collaboration payment of $613 million anticipated in Q3 2026.
The company is focusing investments on late-stage oncology pipeline including Pumitamig, ADCs, and mRNA immunotherapies.
Strategic shift from platform-centric to tumor-centered approach targeting high incidence cancers to drive future sales.
Plans to expand commercial capabilities, supporting upcoming oncology product launches.

2 more points from BioNTech SE's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

BioNTech expects full-year 2026 total revenues in the range of $2 billion to $2.3 billion, despite lower COVID-19 vaccine sales.
Adjusted R&D expenses projected between $2.2 billion and $2.5 billion, focusing on late-stage oncology programs.
Adjusted SG&A expenses anticipated at $700 million to $800 million, reflecting commercial build-out in oncology.
Company emphasizes accelerating late-stage development and combination therapy strategies to drive future growth.
Commitment to becoming a diversified multiproduct oncology company by 2030, leveraging strong balance sheet ($16.8 billion cash) for sustained pipeline investment.

2 more points from BioNTech SE's call on margins

Pro opens every point from 15K+ earnings calls

See what BioNTech SE said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

BioNTech is actively investing in late-stage oncology programs, focusing resources on priority products such as Pumitamig, ADC assets, mRNA immunotherapies, and respective combinations.
The company plans to continue building commercial capabilities, particularly in oncology, reflected in SG&A expense increases.
Manufacturing footprint consolidation is underway, including exploring divestment options for manufacturing sites, expecting around $500 million in annual savings fully implemented by end of 2026.
BioNTech’s balance sheet strength supports ongoing R&D investment and preparations for commercialization.
A $1 billion share repurchase program over the next 12 months reflects confidence in the business but does not reduce innovation investments.

2 more points from BioNTech SE's call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

No specific mention of current or upcoming fundraising through debt or equity in the call transcript.
BioNTech highlights a strong financial position with $16.8 billion in cash, cash equivalents, and investments.
There is an emphasis on disciplined capital allocation to support pipeline and commercialization efforts.
A $1 billion share repurchase program over 12 months is planned, signaling confidence and capital management rather than raising new equity.

2 more points from BioNTech SE's call on fundraising

Pro opens every point from 15K+ earnings calls

See what BioNTech SE said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript does not explicitly disclose specific details about BioNTech's current or expected order book or pending orders. However, relevant points include: - Revenues for Q1 2026 were $118 million, reflecting seasonal demand patterns for COVID-19 vaccines. - Full-year 2026 revenue guidance reaffirmed at $2 billion to $2.3 billion, with lower COVID-19 vaccine revenues expected due to declining demand, particularly in the U.S. and Europe. - COVID-19 vaccine revenue will primarily be driven by the last four months of 2026. - Collaboration payment from BMS of $613 million expected in Q3 2026.

2 more points from BioNTech SE's call on order book

Pro opens every point from 15K+ earnings calls

Others in Biotechnology this season

Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a

Compare:vs AbbVie Inc.vs Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

BioNTech SE and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were BioNTech SE Q2 FY26 results?

- BioNTech reaffirms 2026 revenue guidance of $2 billion to $2.3 billion, despite lower COVID-19 vaccine demand. - BioNTech expects full-year 2026 total revenues in the range of $2 billion to $2.3 billion, despite lower COVID-19 vaccine sales.

What is BioNTech SE share price analysis?

BioNTech SE currently shows a neutral. The stock trades at a P/E of -17.6 with a market cap of $23,484. Investors should review the full earnings analysis for detailed insights.

Is BioNTech SE planning capital expenditure?

- BioNTech is actively investing in late-stage oncology programs, focusing resources on priority products such as Pumitamig, ADC assets, mRNA immunotherapies, and respective combinations.

Keep BioNTech SE on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.